Cardiovascular preventive activities in primary care;Actividades preventivas cardiovasculares en atención primaria

Atencion Primaria

Volumn 32, Issue SUPPL. 2, 2003, Pages 15-29

  Villar Alvarez F ^a   Maiques Galan A ^a   Brotons Cuixart, C ^a   Torcal Laguna, J ^a   Ortega Sanchez Pinilla R ^a   Vilaseca Canals, J ^a   Fores Garcia D ^a   Banegas Banegas, J R ^a   Lobos Bejarano, J M ^a   Orozco Beltran D ^a   Gil Guillen V F ^a   Llor Vila, C ^a   Lorenzo Piqueres, A ^a   Navarro Perez J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CIMETIDINE; COLESTYRAMINE; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; LOSARTAN; MACROLIDE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MORBIDITY; MORTALITY; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SPAIN;

EID: 9144268491     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Instituto Nacional de Estadística. Defunciones según la Causa de Muerte 2000. Madrid: Instituto Nacional de Estadística, 2003.
2. Villar Álvarez F, Banegas JR, Rodríguez Artalejo F, Rey Calero J. Mortalidad cardiovascular en España y sus Comunidades Autónomas (1975-1992). Med Clin (Barc) 1998;110:321-7.
3. World Health Organization. World Health Statistics Annual 1995. Ginebra: WHO, 1996.
4. Sans S, Kesteloot H, Kromhout D, et al. The burden of cardiovascular disease mortality in Europe. Task Force on the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-48.
5. Villar Álvarez F, Banegas Banegas JR. Reducir las enfermedades cardiovasculares. En: Alvarez Dardet C, Peiró S, editores. La salud pública ante los desafíos de un nuevo siglo. Informe SESPAS 2000. Madrid: SESPAS, 2000.
6. Instituto Nacional de Estadística. Encuesta de Morbilidad Hospitalaria. Año 2000. Madrid: Instituto Nacional de Estadística, 2003.
7. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999;353:1547-57.
8. Pérez G, Pena A, Sala J, Roset P, Masiá R, Marrugat J. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. Int J Epidemiol 1998;27:599-604.
9. Banegas JR, Díez Gañán L, Rodríguez Artalejo F, González Enríquez J, Graciani Pérez-Regadera A, Villar Alvarez F. Mortalidad atribuible al tabaquismo en España en 1998. Med Clin (Barc) 2001;117:692-4.
10. Ministerio de Sanidad y Consumo. Encuesta Nacional de Salud de España 1997. Madrid: Ministerio de Sanidad y Consumo, 1999.
11. Ministerio de Sanidad y Consumo. Encuesta Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo, 1989.
12. Banegas Banegas JR, Villar Álvarez F, Pérez de Andrés C, Jiménez García-Pascual R, Gil López E, Muñiz García J, et al. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Pub 1993;67:419-45.
13. Banegas JR, Rodríguez Artalejo F, Cruz JJ, Guallar P, Rey J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998;32:998-1002.
14. Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, Cruz JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens 2002;20:2157-64.
15. Gutiérrez Fuentes JA, Gómez Gerique J, Gómez de la Cámara A, Rubio MA, García Hernández A, Aristegui I. Dieta y riesgo cardiovascular en España (DRECE II). Descripción de la evolución del perfil cardiovascular. Med Clin (Barc) 2000;115:726-9.
16. Civeira F, Serrano P, Banegas JR, Vegazo O, Mantilla T, Luengo E, et al. Prevalencia del diagnóstico y control de dislipemia en pacientes ambulatorios atendidos en el sistema sanitario español. Estudio Hispalipid. XVI Congreso Nacional de la Sociedad Española de Arteriosclerosis; 2003; Málaga.
17. Maiques A, Morales MM, Franch M, Alfonso MD, Moreno-Manzanaro P, García JM. Cálculo del riesgo coronario de los pacientes incluidos en el Programa de Actividades Preventivas y de Promoción de la Salud. Aten Primaria 1995;15:86-92.
18. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
19. Hansson L. Current and future strategies in the treatment of hypertension. Am J Cardiol 1988;61:C2-7.
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.
21. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
22. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45.
23. Pahor M, Psaty BM, Alderman MH, Applegate WB, Willianson JD, Cavazzini Ch, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
24. He J, Whelton PK. Selection of initial antihypertensive therapy. Lancet 2000;356:1942-3.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
27. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
28. World Health Organization-International Society of Hypertension. 1999 World Health Organization-International Society of Hypertension Guidelines for the Managemant of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
29. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
30. Sever P. The SCOPE Trial. J Renin Angiotensin Aldosterone Syst 2002;3:61-2.
31. Viberti G, Wheeldon NM, et al. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus. A Blood Pressure-Independent Effect. Circulation 2002;106:672-8.
32. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: metaanalysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.
33. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-85.
34. Medical Research Council Working Party. MRC trial on treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
35. Systolic Hypertension in Elderly Patients (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-64.
36. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Betablockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335-71.
37. Flather M, Kober L, Pfeffer MA. Meta-analysis of individual patient data from trials of long term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies). Circulation 1997;96(Suppl 1):1-706.
38. Rotaeche del Campo R, et al. Guía de práctica clínica sobre hipertensión arterial. Vitoria: Gobierno Vasco, 2002.
39. Kaplan NM. The meaning of ALLHAT. J Hypertens 2003;21:233-4.
40. Packer M, O'Conner CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
41. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction of incidence of CHD. JAMA 1984;251:351-64.
42. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
43. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
44. Shepherd J, Cobe S, Ford I, Isles C, Ross A, Macfarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
45. Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
46. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
47. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
48. Sacks F, Pleiffer M, Moye L, Rouleau J, Cole T. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol events. N Engl J Med 1996;335:1001-9.
49. Long-term Intervention with Pravastatin in ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
50. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 1999;341:410-8.
51. Serruys PW, Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
52. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerids in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7.
53. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
54. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
55. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983-6.
56. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
57. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Estimación del ríesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003;56:253-61.
58. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997;314:1666-74.
59. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. BMJ 1995;310:1099-104.
60. Family Heart Study Group. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British Family Heart Study. BMJ 1994;308:313-20.
61. Wonderling D, Langham S, Buxton M, Normand C, McDermott C. What can be concluded from the Oxcheck and British Family Heart Studies. Commentary on cost effectiveness analyses. BMJ 1996;312:1274-8.
62. Sierra A, Ruilope LM, Coca A, Luque-Otero M (Grupo Español de Estudios Cardiovasculares). Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos. Med Clin (Barc) 2000;115:41-5.
63. Wood D, De Backe G, Faegerman O, Graham I, Mancia G, Pyörala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
64. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiologia, Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. Rev Esp Salud Pub 2000;74:215-53.
65. Grupo de Prevención Cardiovascular del Programa de Actividades Preventivas y Promoción de la Salud (PAPPS) de la Sociedad Española de Medicina de Familia y Comunitaria (semFYC). Guía de prevención cardiovascular. Madrid: SERSA, 1996.
66. Jackson R, Barham P, Bills J, Birch T, et al. Management of raised pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
67. Grundy SM. Primary prevention of coronary heart disease. Integrating risk assessment with intervention. Circulation 1999;100:988-98.
68. National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
69. Anderson KM, Wilson PWF, Odell PM, Kannel WB. Un update coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
70. Ministerio de Sanidad y Consumo, Sociedad-Liga Española para la lucha contra la Hipertensión Arterial. Control de la Hipertensión Arterial en España, 1996. Madrid: Ministerio de Sanidad y Consumo, 1996.
71. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80:S1-29.
72. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000;21:365-70.
73. Menotti A, Lanti M, Puddu E, Kromhout. Coronary Heart disease incidence in northern and southern European population: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000;84:238-44.
74. Sociedad Española de Arteriosclerosis y Sociedad Española de Cardiología. Evidencias clinicoexperimentales y recomendaciones para el tratamiento de la hiperlipidemia en pacientes con cardiopatía isquémica. Clin Invest Arterioscl 1994;6:103-11.
75. Sociedad Española de Hipertensión-Liga Española para la lucha contra la Hipertensión Arterial. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. Hipertension 2002;19(Supl 3):1-74.
76. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
77. American Diabetes Association. Clinical Practice Recommendations. Diabetes Care 2002;25(Suppl 1):S1-147.
78. Grupo de Dislipemia y Diabetes de la Sociedad Española: de Medicina de Familia y Comunitaria. Abordaje de la dislipemia en la diabetes mellitus en atención primaria [en prensa]. Aten Primaria 2003.